Back to Authors

Monks, Bobby R.

Mayo Clinic

Howard Hughes Medical Institute

Citations 1

Akt and CHIP coregulate tau degradation through coordinated interactions
Dickey, Chad A. , Koren, John , Zhang, Yong‐Jie , Xu, Ya-Fei, Jinwal, Umesh K., Birnbaum, Morris J. , Monks, Bobby R., Sun, Mei , Cheng, Jin , Patterson, Cam, Bailey, Rachel M. , Dunmore, Judith, Soresh, Sareh, Leon, Carlos M.M.P., Morgan, Dave, Petrucelli, Leonard , Zhang, Yong-Jie

Proceedings of the National Academy of Sciences | February 21, 2008 | Volume: 105 | Issue: 9 | Pages: 3622-3627

10.1073/pnas.0709180105 Get It

A hallmark of the pathology of Alzheimer's disease is the accumulation of the microtubule-associated protein tau into fibrillar aggregates. Recent studies suggest that they accumulate because cytosolic chaperones fail to clear abnormally phosphorylated tau, preserving a pool of toxic tau intermediates within the neuron. We describe a mechanism for tau clearance involving a major cellular kinase, Akt. During stress, Akt is ubiquitinated and degraded by the tau ubiquitin ligase CHIP, and this largely depends on the Hsp90 complex. Akt also prevents CHIP-induced tau ubiquitination and its subsequent degradation, either by regulating the Hsp90/CHIP complex directly or by competing as a client protein with tau for binding. Akt levels tightly regulate the expression of CHIP, such that, as Akt levels are suppressed, CHIP levels also decrease, suggesting a potential stress response feedback mechanism between ligase and kinase activity. We also show that Akt and the microtubule affinity-regulating kinase 2 (PAR1/MARK2), a known tau kinase, interact directly. Akt enhances the activity of PAR1 to promote tau hyperphosphorylation at S262/S356, a tau species that is not recognized by the CHIP/Hsp90 complex. Moreover, Akt1 knockout mice have reduced levels of tau phosphorylated at PAR1/MARK2 consensus sites. Hence, Akt serves as a major regulator of tau biology by manipulating both tau kinases and protein quality control, providing a link to several common pathways that have demonstrated dysfunction in Alzheimer's disease.